Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IBD vs RISN: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

RISN Wins Head-to-Head Institutional Verdict (0–0 across 6 Pillars · 2–1 Matrix Metrics)

RISN Overall Winner 6-Pillar Tally: IBD 0 – 0 RISN (6 Tie) Matrix Metrics: IBD 1 – 2 RISN

As of Nov 16, 2026, Inspire Tactical Balanced ETF (RISN) is the stronger overall head-to-head candidate over Inspire Corporate Bond ETF (IBD) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). IBD carries a Unified Composite Score of 44.1/100 (HOLD) at $23.10 (N/M Forward P/E, N/A operating margin), whereas RISN carries 57.5/100 (HOLD) at $30.76 (N/M Forward P/E, N/A operating margin).

  • Technical & Structure Timing Caution: IBD is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.3); meanwhile RISN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IBD vs RISN
IBD NYSE Arca
Inspire Corporate Bond ETF
Institutional Equity
$23.10
-0.04% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.11β · 5% Vol
Unified Composite Score
44.1 / 100 HOLD
Tech 49.0 Fund 51.0 Flow 50.0 Mom 54.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -0.7%) with fading momentum, RSI 44
RSI-14: 44.3 · SMA20: $23.22 · SMA50: $23.20
RISN NYSE Arca Head-to-Head Winner
Inspire Tactical Balanced ETF
Institutional Equity
$30.76
-1.05% 1D
Market Cap N/A
TTM Revenue N/A
Forward P/E N/M
Beta / 30D Vol 0.55β · 15% Vol
Unified Composite Score
57.5 / 100 HOLD
Tech 67.0 Fund 54.0 Flow 50.0 Mom 60.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 52
RSI-14: 52.1 · SMA20: $30.78 · SMA50: $30.56

6-Pillar Scorecard Institutional Category Breakdown (IBD 0 – 0 RISN)

Columns: Metric · IBD · RISN
1. Valuation Multiples Tie
Forward P/E N/M N/M
Trailing P/E N/M N/M
PEG Ratio N/M N/M
EV / Revenue N/M N/M
2. Growth & Scale Tie
Revenue Growth (YoY) N/A N/A
Earnings Growth (YoY) N/A N/A
TTM Revenue (USD) N/A N/A
Market Cap N/A N/A
3. Profitability & Quality Tie
Gross Margin N/A N/A
Operating Margin N/A N/A
Net Profit Margin N/A N/A
Return on Equity (ROE) N/A N/A
4. Balance Sheet & Cash Flow Tie
Cash Generation (TTM) N/A N/A
Cash Flow Margin N/A N/A
Net Cash / Leverage N/A ROE N/A ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile N/A (N/A) N/A (N/A)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Institutional Equity Operator Institutional Equity Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IBD (1) vs RISN (2)
Institutional Metric IBD RISN Criterion Row Edge
Market Capitalization
Scale
N/A N/A Larger Scale Tie
Trailing P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
N/A N/A Higher Growth Tie
Operating Margin (TTM)
Profitability
N/A N/A Higher Margin Tie
Net Profit Margin
Profitability
N/A N/A Higher Margin Tie
Return on Equity (ROE)
Capital Efficiency
N/A N/A Higher ROE Tie
52-Week Range Position
Momentum
26% ($22–$25) 64% ($28–$32) Stronger Trend RISN
Beta / 30D Volatility
Risk Regime
0.11β · 5% Vol 0.55β · 15% Vol Lower Realized Risk IBD
Unified Institutional Score
Composite Signal
44.1 / 100 (HOLD) 57.5 / 100 (HOLD) Higher Composite RISN
Trailing 12M Revenue (USD)
Operating Scale
N/A N/A FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
N/A N/A Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · N/M EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
N/A (N/A ROE) N/A (N/A ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon RISN +1.66 pp
IBD: -0.56% · RISN: +1.1%
3M Horizon RISN +0.32 pp
IBD: -2.37% · RISN: -2.05%
6M Horizon RISN +7.46 pp
IBD: -2.78% · RISN: +4.68%
1Y Horizon RISN +10.39 pp
IBD: -4.39% · RISN: +6.0%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on IBD vs RISN. Trailing 12-month operating profitability (IBD N/A vs RISN N/A) and valuation multiples (IBD N/M vs RISN N/M Forward P/E) are benchmarked directly in Pillar 4 below.

IBD ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M
RISN ADR TTM Benchmark FX-Normalized USD
TTM RevenueN/A
Gross MarginN/A
Op. MarginN/A
ROE / Fwd P/EN/A · N/M

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IBD UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IBD Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
RISN UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact RISN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IBD Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
RISN Moat Profile Cyclical / Execution-Driven Positioning
Institutional Equity Operator
Competes within the Institutional Equity value chain with N/A market capitalization and N/A operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IBD vs RISN Key Questions & Quantitative Answers

As of Nov 16, 2026, Inspire Tactical Balanced ETF (RISN) is the stronger overall head-to-head candidate over Inspire Corporate Bond ETF (IBD) in the Tradestie Institutional Equity Comparison Engine, winning 2–1 core matrix metrics and 0–0 across our 6-pillar institutional scorecard (led by composite factor balance). IBD carries a Unified Composite Score of 44.1/100 (HOLD) at $23.10 (N/M Forward P/E, N/A operating margin), whereas RISN carries 57.5/100 (HOLD) at $30.76 (N/M Forward P/E, N/A operating margin). Technical & Structure Timing Caution: IBD is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 44.3); meanwhile RISN trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 52.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IBD and RISN split Growth & Scale metrics: IBD posts N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin), compared with RISN at N/A YoY revenue growth and N/A YoY earnings growth on N/A TTM revenue (N/A gross margin, N/A operating margin). On trailing 12-month operating scale, IBD generates N/A in USD-normalized revenue versus N/A for RISN. In operating R&D and SG&A reinvestment, IBD deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for RISN.

IBD and RISN trade at balanced relative valuation multiples. IBD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin), whereas RISN trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IBD (N/A ROE) versus RISN (N/A ROE) capital efficiency.

In options market volatility and institutional positioning, IBD carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.11β · 5% Vol realized risk). By comparison, RISN carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.55β · 15% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.